Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1466]

European Commission approves nivolumab for first-line and previously-treated advanced melanoma patients

European Commission approves nivolumab for first-line and previously-treated advanced melanoma patients

Oral cancer therapy combination prevents progression of advanced melanoma for over a year

Oral cancer therapy combination prevents progression of advanced melanoma for over a year

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: Extensive lymph node surgery may not be necessary for some patients with melanoma

ASCO 2015: Extensive lymph node surgery may not be necessary for some patients with melanoma

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

Simple oral vitamin reduces risk of common, non-melanoma skin cancers

Simple oral vitamin reduces risk of common, non-melanoma skin cancers

Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment

Trial of new ‘resistance-busting’ skin cancer drug begins as first patient receives treatment

The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients

The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients

More from ecancer